CY1107849T1 - Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος - Google Patents

Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος

Info

Publication number
CY1107849T1
CY1107849T1 CY20081100024T CY081100024T CY1107849T1 CY 1107849 T1 CY1107849 T1 CY 1107849T1 CY 20081100024 T CY20081100024 T CY 20081100024T CY 081100024 T CY081100024 T CY 081100024T CY 1107849 T1 CY1107849 T1 CY 1107849T1
Authority
CY
Cyprus
Prior art keywords
fumaric acid
asthma treatment
acid producers
heart deficiency
treatment
Prior art date
Application number
CY20081100024T
Other languages
English (en)
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Christian Zaugg
Michael Tamm
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04764790A external-priority patent/EP1663197B1/en
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of CY1107849T1 publication Critical patent/CY1107849T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Σύμφωνα με μια πρώτη πτυχή η εφεύρεση αφορά τη χρήση παραγώγων φουμαρικού οξέος που επιλέγονται από την ομάδα η οποία συνίσταται από διαλκυλικά φουμαρικά, υδρογονούχα μονοαλκυλικά φουμαρικά, άλατα μονοαλκυλ εστέρων φουμαρικού οξέος, μονοαμίδια φουμαρικού οξέος, μονοαμιδο άλατα φουμαρικού οξέος, διαμίδια φουμαρικού οξέος, μονοαλκυλικά μονοαμιδο φουμαρικά, καρβοκυκλικά και οξακαρβοκυκλικά ολιγομερή αυτών των ενώσεων και μείγματα τους για παρασκευή ενός φαρμάκου για τη θεραπεία ή πρόληψη καρδιακής ανεπάρκειας, ειδικότερα ανεπάρκειας της αριστερής κοιλίας, εμφράγματος μυοκαρδίου και στηθάγχης. Σύμφωνα με μια δεύτερη πτυχή η εφεύρεση αφορά τη χρήση παραγώγων φουμαρικού οξέος, που επιλέγονται από την ομάδα η οποία συνίσταται από διαλκυλικά φουμαρικά, υδρογονούχα μονοαλκυλικά φουμαρικά, άλατα μονοαλκυλ εστέρων φουμαρικού οξέος, μονοαμιδο άλατα φουμαρικού οξέος, διαμίδια φουμαρικού οξέος, μονοαλκυλικά μονοαμιδο φουμαρικά, καρβοκυκλικά και οξακαρβοκυκλικά ολιγομερή αυτών των ενώσεων και μείγματα τους για παρασκευή ενός φαρμάκου για τη θεραπεία άσθματος και χρόνιων αποφρακτικών πνευμονικών νόσων, ειδικότερα του άσθματος που προκαλείται από αλλεργίες, μολύνσεις, αναλγητικά, επαγγελματικές συνθήκες ή σωματική προσπάθεια, ανάμεικτες μορφές άσθματος, ή καρδιακού άσθματος.
CY20081100024T 2003-09-09 2008-01-08 Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος CY1107849T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10341530 2003-09-09
DE10360869A DE10360869A1 (de) 2003-09-09 2003-12-23 Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
EP04764790A EP1663197B1 (en) 2003-09-09 2004-09-03 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Publications (1)

Publication Number Publication Date
CY1107849T1 true CY1107849T1 (el) 2013-06-19

Family

ID=34258515

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100024T CY1107849T1 (el) 2003-09-09 2008-01-08 Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος

Country Status (12)

Country Link
JP (3) JP2008529959A (el)
CN (2) CN102058574B (el)
AT (1) ATE447946T1 (el)
CY (1) CY1107849T1 (el)
DE (2) DE10360869A1 (el)
HK (1) HK1094650A1 (el)
IL (1) IL171987A (el)
NZ (1) NZ543708A (el)
PT (1) PT1663197E (el)
RS (1) RS51881B (el)
RU (2) RU2459621C2 (el)
ZA (1) ZA200601985B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2806444C (en) 2008-08-19 2016-02-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
SI2379063T2 (sl) * 2009-01-09 2021-09-30 Fwp Ip Aps Farmacevtska formulacija, ki obsega enega ali več estrov fumarne kisline v tableti v erozivnem matriksu
HK1252751A1 (zh) * 2009-01-09 2019-05-31 Fwp Ip Aps 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑
EP2782561A1 (en) * 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130216615A1 (en) * 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
JP2015526476A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR101379427B1 (ko) * 2013-02-13 2014-03-28 경북대학교병원 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
PL392748A1 (pl) * 2001-01-12 2011-05-09 Fumapharm Ag Amidy kwasu fumarowego
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
RU2189813C1 (ru) * 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Лекарственное средство антигипоксического действия
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere

Also Published As

Publication number Publication date
CN102058574A (zh) 2011-05-18
RU2007138216A (ru) 2009-04-20
DE602004024143D1 (de) 2009-12-24
JP2015155480A (ja) 2015-08-27
ATE447946T1 (de) 2009-11-15
HK1094650A1 (en) 2007-04-04
JP5784877B2 (ja) 2015-09-24
RU2012115860A (ru) 2013-10-27
NZ543708A (en) 2008-11-28
IL171987A0 (en) 2006-04-10
RS51881B (sr) 2012-02-29
CN102058574B (zh) 2013-02-13
CN1829505A (zh) 2006-09-06
ZA200601985B (en) 2007-05-30
RU2459621C2 (ru) 2012-08-27
JP2008529959A (ja) 2008-08-07
CN1829505B (zh) 2010-11-10
JP2010070563A (ja) 2010-04-02
IL171987A (en) 2010-12-30
PT1663197E (pt) 2007-12-26
DE10360869A1 (de) 2005-04-07
RS20050948A (en) 2008-04-04

Similar Documents

Publication Publication Date Title
CY1107849T1 (el) Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
EA200101166A1 (ru) Ингибиторы металлопротеаз
EA200900279A1 (ru) Арилсульфонамиды с аналгетическим действием
CY1112800T1 (el) Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας
YU65804A (sh) Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze
AR034173A1 (es) Un compuesto de piperazina sustituida, composiciones farmaceuticas y el uso de los mismos para la elaboracion de medicamentos
UY27097A1 (es) Derivados del indol
ME01310B (me) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
DE50011582D1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
PT1041072E (pt) Acidos dioxociclopentil hidroxamicos
RU94040170A (ru) Изохинолины
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
SE9900961D0 (sv) Novel compounds
NO20091182L (no) 2-fenoksypyrimidinonanaloger
RU94015265A (ru) Производные пиразина и их кислотно-аддитивные соли
DE602007013040D1 (de) 4-Ä(3-FLUORPHENOXY)PHENYLMETHYLÜPIPERIDINMETHANiSULFONAT: VERWENDUNGEN, SYNTHESEVERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
UY27975A1 (es) Derivados de indolilo
ES2163805T3 (es) Derivados de acidos benzofurano-acrilicos y su utilizacion como moduladores de los receptores rxrs o rars.
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1